Sodium–glucose co-transporter 2 inhibitor has a modest and dose-independent BP-lowering effect in patients with TRH and CKD,181 although SGLT2i reduced risk of CV death in CKD.182 A combination of SGLT2is may reduce the risk of hyperkalaemia-associated outcomes in MRA users with concomitant CKD. The gene discussed is TRH; the disease is chronic kidney disease.